These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853 [TBL] [Abstract][Full Text] [Related]
4. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955 [TBL] [Abstract][Full Text] [Related]
5. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors. Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788 [TBL] [Abstract][Full Text] [Related]
6. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population. Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710 [TBL] [Abstract][Full Text] [Related]
7. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039 [TBL] [Abstract][Full Text] [Related]
8. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785 [TBL] [Abstract][Full Text] [Related]
9. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951 [TBL] [Abstract][Full Text] [Related]
10. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant. Wu S; Liu Y; Shi X; Zhou W; Zeng X Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort. Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas. Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422 [TBL] [Abstract][Full Text] [Related]
13. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform. Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612 [No Abstract] [Full Text] [Related]
15. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886 [TBL] [Abstract][Full Text] [Related]
16. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002 [TBL] [Abstract][Full Text] [Related]
17. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640 [TBL] [Abstract][Full Text] [Related]
18. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
19. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma. Su YJ; Lee YH; Jin YT; Hsieh MS Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876 [TBL] [Abstract][Full Text] [Related]
20. NTRK fusions and Trk proteins: what are they and how to test for them. Weiss LM; Funari VA Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]